TippingPoint Biosciences

Stub active Updated Apr 2, 2026

This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.

Location San Francisco, CA
Founded ~2025
Latest Stage Seed
Total Raised $4.5M

Investors

sosv Seed (2026)

Founders

Laura Hsieh, PhD CEO & Co-Founder
Geeta Narlikar, PhD Co-Founder

About

TippingPoint Biosciences is a drug discovery startup co-founded by Laura Hsieh, PhD, and chromatin biologist Geeta Narlikar, PhD, of UCSF 1. The company develops a platform targeting epigenetic protein interfaces previously considered “undruggable” by recreating disease-specific chromatin environments to reveal transient protein-protein interactions unique to pathological states 1. Their initial focus is Diffuse Intrinsic Pontine Glioma (DIPG), an aggressive pediatric brainstem tumor with no FDA-approved therapies 1. The company has 9 employees and is headquartered in San Francisco 1.

Funding History

Date Round Amount Lead Co-investors
2026-03-31 Seed $4.5M SOSV, LKS Fund Sazze Partners, Freeflow Ventures, StoryHouse Ventures, Sontag Innovation Fund, American Cancer Society BrightEdge, XEIA, WeCAN 1

What Investors Say

No verified investor quotes available at this time.

What Founders Say

No verified founder quotes available at this time.

Sources


  1. BioSpace, “TippingPoint Biosciences Raises $4.5M Seed to Drug Hidden Epigenetic Targets in Deadly Pediatric Brain Cancer,” March 31, 2026. https://www.biospace.com/press-releases/tippingpoint-biosciences-raises-4-5m-seed-to-drug-hidden-epigenetic-targets-in-deadly-pediatric-brain-cancer